News
Pharmaceutical Technology on MSN4d
ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60 to 74 at high risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback